TSN 0.00% 1.0¢ the sustainable nutrition group ltd

Ann: Preliminary Final Report and Financial State, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,698 Posts.
    lightbulb Created with Sketch. 72
    re: Ann: Preliminary Final Report and Financi... Nice outlook

    "FY 2014 Outlook
    Charles Walker, Alchemia’s CEO, commented, “It is exciting to see the progress made over the year across
    our assets, and in particular taking fondaparinux and HA-Irinotecan to major value points. HA-Irinotecan is
    near the completion stage of its pivotal Phase III trial, with top line results expected in H1 CY 2014. Our first
    drug to market, fondaparinux, now has established revenue streams with the potential for further growth
    through new market approvals and cost reductions. We are now aggressively pursuing the various options
    open to us to maximise the shareholder value for both these assets. FY 14 promises to be a watershed year
    for Alchemia.”"


 
watchlist Created with Sketch. Add TSN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.